Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL A SCANNON

Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology

NPI
1396734851
CMS profile
199370
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$23,784.29

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $16,591.03 20
Amgen Inc. $6,889.23 12
Novartis Pharmaceuticals Corporation $304.03 4

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL A SCANNON

NPI 1396734851 · CMS profile ID 199370

Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396734851?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL A SCANNON, NPI 1396734851, CMS profile ID 199370. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396734851?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MICHAEL A SCANNON, NPI 1396734851, CMS profile ID 199370. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396734851?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MICHAEL A SCANNON, NPI 1396734851, CMS profile ID 199370, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1396734851?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $23,784.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $1,650.0012/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112903 CMS
AbbVie Inc. $1,650.0012/15/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112901 CMS
AbbVie Inc. $12.7012/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112899 CMS
AbbVie Inc. $1,650.0012/07/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112897 CMS
AbbVie Inc. $12.7012/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112895 CMS
AbbVie Inc. $1,650.0011/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112893 CMS
AbbVie Inc. $1,650.0011/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112891 CMS
AbbVie Inc. $8.6211/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112889 CMS
AbbVie Inc. $1,650.0011/02/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112887 CMS
AbbVie Inc. $1,650.0010/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112885 CMS
AbbVie Inc. $8.4109/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112883 CMS
Novartis Pharmaceuticals Corporation $47.7209/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726118721 CMS
AbbVie Inc. $1,650.0008/31/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112881 CMS
Amgen Inc. $500.0008/27/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419055 CMS
AbbVie Inc. $8.2108/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112879 CMS
AbbVie Inc. $412.5006/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112877 CMS
AbbVie Inc. $10.8706/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112875 CMS
Novartis Pharmaceuticals Corporation $120.9206/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726118717 CMS
Amgen Inc. $1,000.0005/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419053 CMS
Amgen Inc. $500.0004/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419051 CMS
AbbVie Inc. $9.3703/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112873 CMS
AbbVie Inc. $10.8602/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112871 CMS
Novartis Pharmaceuticals Corporation $124.8002/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726118715 CMS
Novartis Pharmaceuticals Corporation $10.5901/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726118723 CMS
AbbVie Inc. $2,750.0001/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112869 CMS
AbbVie Inc. $124.7201/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112867 CMS
Amgen Inc. $3,750.0001/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419049 CMS
Amgen Inc. $105.9201/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419057 CMS
Amgen Inc. $35.0401/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419059 CMS
Amgen Inc. $43.1001/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419061 CMS
Amgen Inc. $50.0101/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419063 CMS
Amgen Inc. $72.7801/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419065 CMS
Amgen Inc. $128.0901/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419067 CMS
Amgen Inc. $308.8701/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419069 CMS
Amgen Inc. $395.4201/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741419071 CMS
AbbVie Inc. $22.0701/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722112865 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $52,034.00 62
PY2020 $23,784.29 36
PY2021 $8,523.32 21
PY2022 $39,954.57 43
PY2023 $44,634.72 75
PY2024 $32,493.63 70
PY2025 $16,286.09 64

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $384,924.97 113
PY2024 Principal investigator $161,267.18 64
PY2023 Principal investigator $32,574.72 6
PY2019 Principal investigator $1,240.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,676.27 12/30/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1100763036
Principal investigator 1 ABBVIE INC. $174.24 12/26/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100762622
Principal investigator 1 ABBVIE INC. $1,448.24 12/26/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100762624
Principal investigator 1 ABBVIE INC. $11.38 12/26/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100762640
Principal investigator 1 ABBVIE INC. $3,217.61 12/24/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100762280
Principal investigator 1 ABBVIE INC. $3,350.96 12/24/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100762288
Principal investigator 1 ABBVIE INC. $93.86 12/19/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100761784
Principal investigator 1 ABBVIE INC. $1,200.00 12/19/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100761788
Principal investigator 1 ABBVIE INC. $1,200.00 12/19/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1100761800
Principal investigator 1 ABBVIE INC. $1,600.00 12/12/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100761107
Principal investigator 1 ABBVIE INC. $724.77 12/11/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100760791
Principal investigator 1 ABBVIE INC. $1,449.54 12/11/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100760793
Principal investigator 1 ABBVIE INC. $87.12 12/11/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100760799
Principal investigator 1 ABBVIE INC. $898.62 12/11/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100760829
Principal investigator 1 ABBVIE INC. $160.79 12/10/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100760601
Principal investigator 1 ABBVIE INC. $2,153.00 12/05/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100759133
Principal investigator 1 ABBVIE INC. $70.00 12/05/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100759177
Principal investigator 1 ABBVIE INC. $5,951.00 10/03/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100745722
Principal investigator 1 ABBVIE INC. $65.97 09/18/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100742754
Principal investigator 1 ABBVIE INC. $6,596.77 09/18/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100742756
Principal investigator 1 ABBVIE INC. $63.36 09/18/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100742758
Principal investigator 1 ABBVIE INC. $13,040.00 09/04/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100740098
Principal investigator 1 ABBVIE INC. $664.00 08/08/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100735500
Principal investigator 1 ABBVIE INC. $60.77 08/07/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100735312
Principal investigator 1 ABBVIE INC. $14,035.00 08/02/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1100733842
Principal investigator 1 ABBVIE INC. $13,035.00 08/02/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1100733902
Principal investigator 1 ABBVIE INC. $5,954.00 08/02/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100733904
Principal investigator 1 ABBVIE INC. $225.72 08/01/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100732490
Principal investigator 1 ABBVIE INC. $83.16 07/31/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100731506
Principal investigator 1 ABBVIE INC. $724.77 07/18/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100730188
Principal investigator 1 ABBVIE INC. $3,396.00 07/05/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100726970
Principal investigator 1 ABBVIE INC. $220.74 06/27/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100724856
Principal investigator 1 ABBVIE INC. $43.56 06/17/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100723814
Principal investigator 1 ABBVIE INC. $78.26 06/13/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100723516
Principal investigator 1 ABBVIE INC. $6,876.00 06/06/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100722660
Principal investigator 1 ABBVIE INC. $350.00 06/06/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100722662
Principal investigator 1 ABBVIE INC. $19.20 05/30/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100719894
Principal investigator 1 ABBVIE INC. $664.00 05/16/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100718616
Principal investigator 1 ABBVIE INC. $69.89 05/14/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100718498
Principal investigator 1 ABBVIE INC. $6,364.00 05/09/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100718208
Principal investigator 1 ABBVIE INC. $664.00 05/09/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100718210
Principal investigator 1 ABBVIE INC. $78.94 04/29/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100715254
Principal investigator 1 ABBVIE INC. $3,797.25 04/17/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100714080
Principal investigator 1 ABBVIE INC. $3,049.20 04/16/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100713992
Principal investigator 1 ABBVIE INC. $48.92 04/11/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100713652
Principal investigator 1 ABBVIE INC. $83.16 04/11/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100713654
Principal investigator 1 ABBVIE INC. $118.80 04/04/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100710766
Principal investigator 1 ABBVIE INC. $9,742.00 04/04/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100710822
Principal investigator 1 ABBVIE INC. $43.56 04/04/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100710824
Principal investigator 1 ABBVIE INC. $664.00 03/25/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100709668
Principal investigator 1 ABBVIE INC. $87.12 03/25/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100709670
Principal investigator 1 ABBVIE INC. $5,682.00 03/07/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100706456
Principal investigator 1 ABBVIE INC. $43.56 02/20/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100704188
Principal investigator 1 ABBVIE INC. $170.70 02/08/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100703312
Principal investigator 1 ABBVIE INC. $225.00 02/05/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100702978
Principal investigator 1 ABBVIE INC. $33.00 02/05/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100702980
Principal investigator 1 ABBVIE INC. $3,984.00 02/05/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100702982
Principal investigator 1 ABBVIE INC. $5,872.00 02/05/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100702984
Principal investigator 1 ABBVIE INC. $600.00 02/05/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100702986
Principal investigator 1 ABBVIE INC. $14,717.00 02/02/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100702670
Principal investigator 1 ABBVIE INC. $131.96 01/17/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100700497
Principal investigator 1 ABBVIE INC. $139.72 01/17/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100700499
Principal investigator 1 ABBVIE INC. $139.72 01/17/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100700501
Principal investigator 1 ABBVIE INC. $6,054.00 01/04/2024 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1100698813